Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C E Halstenson

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
Journal of Clinical Pharmacology|February 1, 1992
Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairmentC E Halstenson, J Triscari, A DeVault, et al.
Journal of Clinical Pharmacology|April 1, 1995
Disposition of misoprostol and its active metabolite in patients with normal and impaired renal functionE F Foote, D R Lee, A Karim, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 1, 1995
The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysisE F Foote, Z M Look, P Giles, et al.
American Journal of Nephrology|January 1, 1990
Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patientsP A Abraham, J A Opsahl, K M Rachael, et al.
Investigational New Drugs|February 12, 2016
Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3-1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjectsC E Halstenson, T Shamp, M A Gargano, et al.
Clinical Pharmacokinetics|June 1, 1992
Controversies in determination of epoetin (recombinant human erythropoietin) dosagesP A Abraham, W L St Peter, K A Redic-Kill, et al.
Clinical Chemistry|February 1, 1989
Assessment of renal function by inulin clearance: comparison with creatinine clearance as determined by enzymatic methodsF S Apple, P Benson, P A Abraham, et al.
Journal of Clinical Pharmacology|November 1, 1992
Disposition of cefpodoxime proxetil in hemodialysis patientsM T Borin, G S Hughes, J S Kelloway, et al.
Pharmacotherapy|September 1, 1985
Antihypertensive therapy with once-daily administration of terazosin, a new alpha 1-adrenergic-receptor blockerP A Abraham, C E Halstenson, G R Matzke, et al.
Journal of Clinical Pharmacology|February 1, 1995
Effects of hemodialysis on plasma protein binding of bepridilJ F Pritchard, G R Matzke, J A Opsahl, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Journal of Clinical Pharmacology|February 1, 1992
Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairmentC E Halstenson, J Triscari, A DeVault, et al.
Journal of Clinical Pharmacology|April 1, 1995
Disposition of misoprostol and its active metabolite in patients with normal and impaired renal functionE F Foote, D R Lee, A Karim, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 1, 1995
The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysisE F Foote, Z M Look, P Giles, et al.
American Journal of Nephrology|January 1, 1990
Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patientsP A Abraham, J A Opsahl, K M Rachael, et al.
Investigational New Drugs|February 12, 2016
Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3-1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjectsC E Halstenson, T Shamp, M A Gargano, et al.
Clinical Pharmacokinetics|June 1, 1992
Controversies in determination of epoetin (recombinant human erythropoietin) dosagesP A Abraham, W L St Peter, K A Redic-Kill, et al.
Clinical Chemistry|February 1, 1989
Assessment of renal function by inulin clearance: comparison with creatinine clearance as determined by enzymatic methodsF S Apple, P Benson, P A Abraham, et al.
Journal of Clinical Pharmacology|November 1, 1992
Disposition of cefpodoxime proxetil in hemodialysis patientsM T Borin, G S Hughes, J S Kelloway, et al.
Pharmacotherapy|September 1, 1985
Antihypertensive therapy with once-daily administration of terazosin, a new alpha 1-adrenergic-receptor blockerP A Abraham, C E Halstenson, G R Matzke, et al.
Journal of Clinical Pharmacology|February 1, 1995
Effects of hemodialysis on plasma protein binding of bepridilJ F Pritchard, G R Matzke, J A Opsahl, et al.
Pageof 9